Diagnosis and management of primary aldosteronism
Carregando...
Citações na Scopus
49
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
Sociedade Brasileira de Endocrinologia e Metabologia
Citação
ARCHIVES OF ENDOCRINOLOGY METABOLISM, v.61, n.3, p.305-312, 2017
Resumo
ABSTRACT Primary aldosteronism (PA) is the most common form of secondary hypertension (HTN), with an estimated prevalence of 4% of hypertensive patients in primary care and around 10% of referred patients. Patients with PA have higher cardiovascular morbidity and mortality than age- and sex-matched patients with essential HTN and the same degree of blood pressure elevation. PA is characterized by an autonomous aldosterone production causing sodium retention, plasma renin supression, HTN, cardiovascular damage, and increased potassium excretion, leading to variable degrees of hypokalemia. Aldosterone-producing adenomas (APAs) account for around 40% and idiopathic hyperaldosteronism for around 60% of PA cases. The aldosterone-to-renin ratio is the most sensitive screening test for PA. There are several confirmatory tests and the current literature does not identify a “gold standard” confirmatory test for PA. In our institution, we recommend starting case confirmation with the furosemide test. After case confirmation, all patients with PA should undergo adrenal CT as the initial study in subtype testing to exclude adrenocortical carcinoma. Bilateral adrenal vein sampling (AVS) is the gold standard method to define the PA subtype, but it is not indicated in all cases. An experienced radiologist must perform AVS. Unilateral laparoscopic adrenalectomy is the preferential treatment for patients with APAs, and bilateral hyperplasia should be treated with mineralocorticoid antagonist (spironolactone or eplerenone). Cardiovascular morbidity caused by aldosterone excess can be decreased by either unilateral adrenalectomy or mineralocorticoid antagonist. In this review, we address the most relevant issues regarding PA screening, case confirmation, subtype classification, and treatment.
Palavras-chave
Primary aldosteronism, resistant hypertension, diagnosis, aldosterone, renin
Referências
- Ahmed AH, 2011, J CLIN ENDOCR METAB, V96, P1797, DOI 10.1210/jc.2010-2918
- Beygui F, 2006, CIRCULATION, V114, P2604, DOI 10.1161/CIRCULATIONAHA.106.634626
- Burgess ED, 2003, CLIN THER, V25, P2388, DOI 10.1016/S0149-2918(03)80282-5
- Calhoun DA, 2002, HYPERTENSION, V40, P892, DOI 10.1161/01.HYP.0000040261.30455.B6
- Calhoun DA, 2008, CIRCULATION, V117, pE510, DOI 10.1161/CIRCULATIONAHA.108.189141
- Catena C, 2007, HYPERTENSION, V50, P911, DOI 10.1161/HYPERTENSIONAHA.107.095448
- Celen O, 1996, ARCH SURG-CHICAGO, V131, P646
- Chen W, 2014, IRISH J MED SCI, V183, P283, DOI 10.1007/s11845-013-1007-x
- Dekkers T, 2016, LANCET DIABETES ENDO, V4, P739, DOI 10.1016/S2213-8587(16)30100-0
- Dluhy RG, 1999, J CLIN ENDOCR METAB, V84, P4341, DOI 10.1210/jc.84.12.4341
- Dluhy RG, 2001, J PEDIATR-US, V138, P715, DOI 10.1067/mpd.2001.112648
- Doppman JL, 1996, RADIOLOGY, V198, P309
- Douma S, 2008, LANCET, V371, P1921, DOI 10.1016/S0140-6736(08)60834-X
- Egan BM, 2010, JAMA-J AM MED ASSOC, V303, P2043, DOI 10.1001/jama.2010.650
- El Ghorayeb N, 2016, J CLIN ENDOCR METAB, V101, P1826, DOI 10.1210/jc.2015-3915
- Fallo F, 2006, J CLIN ENDOCR METAB, V91, P454, DOI 10.1210/jc.2005-1733
- Funder JW, 2008, J CLIN ENDOCR METAB, V93, P3266, DOI 10.1210/jc.2008-0104
- Funder JW, 2016, J CLIN ENDOCR METAB, V101, P1889, DOI 10.1210/jc.2015-4061
- Geller DS, 2008, J CLIN ENDOCR METAB, V93, P3117, DOI 10.1210/jc.2008-0594
- Guder G, 2007, CIRCULATION, V115, P1754, DOI 10.1161/CIRCULATIONAHA.106.653964
- Hannemann A, 2012, HORM METAB RES, V44, P157, DOI 10.1055/s-0031-1295438
- JEUNEMAITRE X, 1987, AM J CARDIOL, V60, P820, DOI 10.1016/0002-9149(87)91030-7
- KLOOS RT, 1995, ENDOCR REV, V16, P460, DOI 10.1210/er.16.4.460
- Lafferty AR, 2000, J MED GENET, V37, P831, DOI 10.1136/jmg.37.11.831
- Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676
- LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0
- Milliez P, 2005, J AM COLL CARDIOL, V45, P1243, DOI 10.1016/j.jacc.2005.01.015
- Mulatero P, 2013, J CLIN ENDOCR METAB, V98, P4826, DOI 10.1210/jc.2013-2805
- Mulatero P, 2013, NAT REV ENDOCRINOL, V9, P104, DOI 10.1038/nrendo.2012.230
- Murray CJL, 2013, NEW ENGL J MED, V369, P448, DOI 10.1056/NEJMra1201534
- Nanba K, 2012, J CLIN ENDOCR METAB, V97, P1688, DOI 10.1210/jc.2011-2504
- Pallauf A, 2012, HORM METAB RES, V44, P215, DOI 10.1055/s-0031-1299730
- Parthasarathy HK, 2011, J HYPERTENS, V29, P980, DOI 10.1097/HJH.0b013e3283455ca5
- Plouin PF, 2004, NEPHROL DIAL TRANSPL, V19, P774, DOI 10.1093/ndt/gfh112
- Rossi GP, 2008, HYPERTENSION, V51, P1366, DOI 10.1161/HYPERTENSIONAHA.108.111369
- Rossi GP, 2007, J HYPERTENS, V25, P1433, DOI 10.1097/HJH.0b013e328126856e
- Rossi GP, 2006, J AM COLL CARDIOL, V48, P2293, DOI 10.1016/j.jacc.2006.07.059
- Rossi GP, 2016, CLIN CHEM LAB MED, V54, P1441, DOI 10.1515/cclm-2015-1094
- Rossi GP, 2012, J CLIN ENDOCR METAB, V97, P1606, DOI 10.1210/jc.2011-2830
- Savard S, 2013, HYPERTENSION, V62, P331, DOI 10.1161/HYPERTENSIONAHA.113.01060
- Sawka AM, 2001, ANN INTERN MED, V135, P258
- Scholl UI, 2012, P NATL ACAD SCI USA, V109, P2533, DOI 10.1073/pnas.1121407109
- Stewart PM, 1999, LANCET, V353, P1341, DOI 10.1016/S0140-6736(98)06102-9
- Stowasser M, 2005, J CLIN ENDOCR METAB, V90, P5070, DOI 10.1210/jc.2005-0681
- SUTHERLA.DJ, 1966, CAN MED ASSOC J, V95, P1109
- Tsutamoto T, 2007, CIRC J, V71, P915, DOI 10.1253/circj.71.915
- Tylicki L, 2005, KIDNEY BLOOD PRESS R, V28, P230, DOI 10.1159/000087842
- Vasan RS, 2004, NEW ENGL J MED, V351, P33, DOI 10.1056/NEJMoa033263
- WAMBACH G, 1980, DEUT MED WOCHENSCHR, V105, P647, DOI 10.1055/s-2008-1070723
- Yoneda T, 2016, J CLIN ENDOCR METAB, V101, P2554, DOI 10.1210/jc.2016-1011